Bloomberg

Biocon's Mazumdar-Shaw Says Firm On Track To Be Top Insulin Maker

Share

Biocon Executive Chairperson Kiran Mazumdar-Shaw says she is confident that the company's investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg's Haslinda Amin.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.